News&Events

ALL

ALL EVENTS NEWS
NEWS

New Clinical Trial of af-001 for Differentiated Thyroid Cancer Posted on ClinicalTrials.gov

NEWS

Alpha Fusion Initiates Company-Sponsored Clinical Trial of Alpha-Emitting Radiopharmaceutical af-001 in Patients with Differentiated Thyroid Cancer

EVENTS

Head of Supply Chain Development Kohno is scheduled to give a presentation at the 7th Targeted Radiopharmaceuticals Summit Europe.

EVENTS

CEO Fujioka and Head of Supply Chain Development Kohno are scheduled to attend Bio-Europe 2025 (Vienna).

NEWS

A clinical trial report on the investigator-initiated Alpha-T1 study by our collaborator, Associate Professor/Lecturer Dr. Watabe from the University of Osaka Graduate School of Medicine, was published in The Journal of Nuclear Medicine.

EVENTS

A review article on At-PSMA-5 by our collaborator, Associate Professor/Lecturer Dr. Watabe from the University of Osaka Graduate School of Medicine, was published in Seminars in Nuclear Medicine.

NEWS

A clinical trial report on the investigator-initiated Alpha-T1 study by our collaborator, Associate Professor/Lecturer Dr. Watabe from the University of Osaka Graduate School of Medicine, was published in The Journal of Nuclear Medicine.

NEWS

Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals

NEWS

Alpha Fusion Initiates Joint Research with Mitsubishi Tanabe Pharma and Veneno Technologies

NEWS

Alpha Fusion Accelerates Astatine-based Drug Discovery with Series B Funding

NEWS

Business Briefing Held at Osaka University TAT Cyclotron Building

NEWS

Initiation of Clinical Trial Using Astatine for Refractory Prostate Cancer

NEWS

Alpha Fusion Begins R&D for Novel Astatine Labeling Platform Technology

NEWS

Alpha Fusion and QST Commence R&D for Multiple Novel Astatine Therapeutics Targeting Proteins Highly Expressed in Tumors

NEWS

Alpha Fusion closes Series A with New Equity Participation by Toshiba Energy Systems